Initiated and Enrolling Patients into MNPR-101-Zr First-in-Human Phase 1 Radiopharma Clinical Trial MNPR-101 radio-immuno-therapeutic (RIT) Clinical Trial on Track to Initiate in Q4 2024 WILMETTE, Ill., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, today announced second quarter 2024 financial results and summarized recent developments. Recent D ...

WILMETTE, Ill., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced that it will effect a 1-for-5 reverse stock split of its outstanding shares of common stock (the "Reverse Stock Split"). The Company expects that the Reverse Stock Split will become effective at 5:00 pm on Monday August 12, 2024, and its common stock will begin trading on a split-adjusted basis at the ...

WILMETTE, Ill., July 09, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced the enrollment of the first patient in its first-in-human Phase 1 dosimetry and imaging clinical trial of MNPR-101-Zr. This novel radiopharmaceutical imaging agent combines MNPR-101, Monopar's antibody that selectively targets the urokinase plasminogen activator receptor (uPAR), with the radioisotope z ...

Core Insights - Monopar Therapeutics Inc. announced that its abstract on MNPR-101-RIT has been accepted as a "Top-Rated Oral Presentation" at the EANM 2024 Annual Congress, highlighting the company's innovative approach in cancer treatment [1][3] Company Overview - Monopar Therapeutics is a clinical-stage radiopharmaceutical company focused on developing treatments for cancer, including the Phase 1-stage MNPR-101-Zr for imaging and the late preclinical-stage MNPR-101 radio-immuno-therapeutic (RIT) for advanced cancers [4] Product Details - MNPR-101-RIT is a first-in-class radio-immuno-therapeutic targeting cancers with the urokinase plasminogen activator receptor (uPAR), such as triple-negative breast, colorectal, and pancreatic cancers [2] - Preclinical data show significant anti-tumor benefits with MNPR-101 when conjugated to therapeutic radioisotopes like lutetium-177 (Lu-177) and actinium-225 (Ac-225) [2] Clinical Trials - The company has initiated a first-in-human Phase 1 imaging and dosimetry clinical trial for MNPR-101-Zr in advanced cancer patients, with further details available on ClinicalTrials.gov [3]

Core Insights - Monopar Therapeutics Inc. has announced that its abstract on "Evaluation of Anti-uPAR Antibody as a Radiopharmaceutical for Imaging and Treatment of Solid Tumors" has been accepted as a "Top-Rated Oral Presentation" at the EANM 2024 Annual Congress [1][2] - The recognition highlights the potential of Monopar's uPAR-targeted therapy and the growing interest in uPAR as a target for radiopharmaceutical treatments [2] Company Overview - Monopar Therapeutics is a clinical-stage radiopharmaceutical company focused on developing innovative cancer treatments, including the Phase 1 MNPR-101-Zr for imaging advanced cancers and the late preclinical-stage MNPR-101 radio-immuno-therapeutic (RIT) for treating advanced cancers [7] - The MNPR-101-RIT program targets cancers expressing the urokinase plasminogen activator receptor (uPAR), such as triple-negative breast, colorectal, and pancreatic cancers [5] Clinical Trials - Monopar has initiated its first-in-human Phase 1 imaging and dosimetry clinical trial for MNPR-101-Zr in advanced cancer patients, with further details available on ClinicalTrials.gov [6]

WILMETTE, Ill. and Beloit, Wis., June 11, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company, and NorthStar Medical Radioisotopes, LLC, a global innovator in development and commercial production of medical radioisotopes, today announced an amendment and expansion to their existing collaboration. Under terms of the revised collaboration, the Companies entered into a long-term, non-exclusive master supply agreement for NorthStar to provide Monopar with the ...

WILMETTE, Ill., June 10, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, is presenting today data from the preclinical development of its novel first-in-class lead radiopharma program MNPR-101-Zr at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Toronto, Canada. SNMMI is the premier educational, scientific, and research event in the radiopharm ...

WILMETTE, Ill., May 24, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that after a career spanning more than 35 years, Monopar's Chief Financial Officer, Kim R. Tsuchimoto, will be retiring. Ms. Tsuchimoto will be transitioning over the next month, with her last day being on June 30, 2024. Ms. Tsuchimoto will remain as a member of Monopar's Board of Directors. Mo ...

WILMETTE, Ill., May 24, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that after a career spanning more than 35 years, Monopar's Chief Financial Officer, Kim R. Tsuchimoto, will be retiring. Ms. Tsuchimoto will be transitioning over the next month, with her last day being on June 30, 2024. Ms. Tsuchimoto will remain as a member of Monopar's Board of Directors. Mo ...

Shares of Monopar Therapeutics Inc. (MNPR) have been struggling lately and have lost 13.2% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road. While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about t ...